Related Experiment Videos
Phase II study of pyrazofurin in advanced colorectal carcinoma
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma.
Investigational new drugs·1999
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
International journal of radiation oncology, biology, physics·1998
Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer.
Cancer chemotherapy and pharmacology·1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
When CO2 sensing fails: Protective effects of sex hormones and potential mechanisms.
Journal of neuroendocrinology·2026
Survival in unresectable hepatocellular carcinoma: Comparison of four treatments based on patients reconstructed from Kaplan-Meier curves of randomized trials.
World journal of gastrointestinal pharmacology and therapeutics·2026
Acupuncture Suppresses the ER Stress-JNK Pathway to Inhibit Chondrocyte Apoptosis and Attenuate Knee Osteoarthritis.
Cell stress & chaperones·2026
Schisantherin B mitigates cisplatin-induced ototoxicity by modulating the CNPY2-PERK/CHOP signaling axis.
Biochemical pharmacology·2026